Compare Apollo Global Management Ord Shs (APO) vs Boston Scientific Corporation (BSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Boston Scientific Corporation — how do they compare? Apollo Global Management Ord Shs trades at $138.01 (market cap $82.84B), while Boston Scientific Corporation trades at $51.54 (market cap $74.19B). The key difference: Apollo Global Management Ord Shs and Boston Scientific Corporation are close in size by market cap, and Apollo Global Management Ord Shs pays a 1.6% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| APO | BSX | |
|---|---|---|
Market Cap | $82.84B | $74.19B |
Sector | Financials | Health |
52-Week High | $152.70 | $108.14 |
52-Week Low | $100.30 | $42.63 |
Enterprise Value | -$168.65B | $86.27B |
Dividend Yield | 1.6% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $137.75, up 4.34% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Q2 2026 earnings missed estimates at $2.11 per share versus $2.16 expected, but revenue growth remains robust with record fee-related earnings. Recent news highlights strategic AI infrastructure deals and a $2.6 billion financing agreement with Yankee Global Enterprises.
Outlook is positive with an 82% analyst buy rating and $151.50 consensus price target, implying 10% upside. Risks include expense growth impacting net margins and competitive pressures in asset management. The company's strong capital formation and perpetual capital base support long-term growth, but investors should monitor execution on AI initiatives and interest rate sensitivity.
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →
